Compare AVDL & DAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVDL | DAC |
|---|---|---|
| Founded | 2015 | 1972 |
| Country | Ireland | Greece |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 1996 | 2006 |
| Metric | AVDL | DAC |
|---|---|---|
| Price | $21.63 | $94.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 1 |
| Target Price | $18.38 | ★ $105.00 |
| AVG Volume (30 Days) | ★ 2.1M | 72.6K |
| Earning Date | 11-04-2025 | 02-09-2026 |
| Dividend Yield | N/A | ★ 3.80% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 25.05 |
| Revenue | $248,517,000.00 | ★ $1,034,370,000.00 |
| Revenue This Year | $65.47 | N/A |
| Revenue Next Year | $30.88 | $1.29 |
| P/E Ratio | ★ N/A | $3.78 |
| Revenue Growth | ★ 79.88 | 2.90 |
| 52 Week Low | $6.38 | $65.40 |
| 52 Week High | $23.57 | $100.00 |
| Indicator | AVDL | DAC |
|---|---|---|
| Relative Strength Index (RSI) | 61.54 | 50.58 |
| Support Level | $21.36 | $92.12 |
| Resistance Level | $21.68 | $95.40 |
| Average True Range (ATR) | 0.12 | 1.85 |
| MACD | -0.12 | -0.31 |
| Stochastic Oscillator | 74.68 | 32.36 |
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.
Danaos Corp is an international owner of containerships. It provides international seaborne transportation services by operating vessels in the containership sector of the shipping industry. The company's customers include, HMM, MSC, Yang Ming, Hapag Lloyd, ZIM, Maersk, COSCO, OOCL, ONE, PIL, Sealead, Niledutch, Samudera, OSC, and Arkas. Geographically, the company operates in Australia-Asia, Europe, and America, with maximum revenue from the Australia-Asia region. It has two reporting segments Container vessels and Drybulk vessels segment. It generates the majority of its revenue from Container vessels.